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Recent histopathological studies revealed that the androgen receptor (AR) is the most commonly expressed hormone receptor in breast cancer, with 75-90% of ER-positive and approximately 30% of ER-negative breast cancers expressing AR (6, 7) . While AR is widely present in breast cancer tissue, accumulating evidence have demonstrated that the role of AR in these tumors are subtype-dependent (8) (9) (10) (11) . AR antagonists including bicalutamide and enzalutamide have been shown to reduce the growth of AR-positive but ER-negative, including triple negative, breast cancer in preclinical models (12) (13) (14) and in patients (11) . In contrast, in ER-positive breast cancers, AR has been considered anti-proliferative and been associated with a favorable prognosis. Clinically, until the 1970s, breast cancers were often treated with nonselective steroidal androgens including testosterone derivatives and danazol with response rates of 20-25% (9, (15) (16) (17) (18) . In line with these clinical experiences, preclinical studies have also shown treatment with classic androgens including dihydrotestosteone (DHT) reduced the growth of AR and ER-positive (AR/ER+) breast cancer cells in vitro (19) (20) (21) and in vivo (22) . Classic androgen-based therapy for breast cancer declined due to its virilizing effects, potential risk of further aromatization to estrogens, and the emergence of ER-targeted agents including tamoxifen. However, it is worth noting that more recent clinical evidence showed androgen treatment also led to remission in patients who were progressing after ER-targeted therapy with objective response rate around 17-39% (23, 24) . Fulvestrant at second line or later in large phase III trials elicited objective response rates of 2.1-11% (25) (26) (27) (28) .
The high prevalence of AR observed in ER-positive breast cancers, along with the prior clinical efficacy demonstrated with classic androgens, provide a strong rationale for the development of a new generation of oral, selective AR agonists and to further exploit their therapeutic benefits in AR/ER+ breast cancer. Here we describe the tissue-selective AR agonist activity of RAD140, an oral nonsteroidal selective AR modulator (SARM), and its distinct AR-mediated mechanism of action including the suppression of ESR1. RAD140 exhibited potent anti-tumor activity in the in 6 ligands DHT, 17β-estradiol, progesterone, and dexamethasone (for AR, ER, PR and GR, respectively) was also measured. The relative binding affinity of RAD140 vs the 4 standard ligands is reflected by the ratios of IC 50 (standard ligand)/ IC 50 (RAD140). A commercially available spectrum screen was performed for RAD140 (MDS Pharma Services, Taipei, Taiwan).
The binding of RAD140 (1 µM) to a panel of cellular targets was assessed (Supplementary Table S1 ). Appreciable binding was defined as a larger than 50% inhibition of the reference radio-ligand.
Cell culture and treatment
The ZR-75-1, HCC1428 and T47D breast cancer cells and LNCaP prostate cancer cells were purchased from American Tissue Type Culture Collection (ATCC, Manassas, VA) and maintained in medium and condition as recommended by the vendor. All cell lines involved in the study were tested negative for mycoplasma contamination (MycoAlert Detection Kit, Lonza, Switzerland) and subjected to annual authentication using STR profiling (Thermo Fisher). All the cells were under passage 15 at the time of experiments. HCC1428 Long Term Estrogen Depleted (LTED) cells were established by culturing these cells in medium with 10% charcoal dextran-stripped serum (CSS) for 16 weeks and the expression of AR, ER, PR were confirmed by western blotting (Supplementary Figure S1A) . For proliferation assay, cells were seeded in medium with 10% CSS at 30,000 cells/well in 24-well plates and subjected to treatment with RAD140, DHT or DMSO for 14 days with treatments being renewed every 3 days. At the end of the treatment period, trypsinized cells were stained with trypan blue before subjected to live cell counting in a Nexcelom Cellometer (Nexcelom Bioscience, Lawrence, MA). The PC3-AR cell line, described previously (29) , was a generous gift from Dr. Steve Balk of Beth Israel 7 final concentration or vehicle (ethanol) before being incubated with dimethyl sulfoxide (DMSO), RAD140 (Radius Health, Inc., as described previously (30) ), or DHT (Sigma Aldrich, Natick, MA) in the presence or absence of enzalutamide or ARN-509 (Selleckchem, Houston, TX) for 24 h.
The experiments were performed in duplicate. The nuclear and cytoplasmic fractions of the cells were prepared using the NE-PER nuclear and cytoplasmic extraction kit (Thermo Fisher) following manufacturer's instructions.
AR reporter gene assays
AR reporter gene assay was carried out using a Cignal Androgen Receptor Reporter (luc) Kit (Qiagen, Valencia, CA). ZR-75-1 breast cancer cells, LNCaP and PC3-AR prostate cancer cells were transfected with a tandem androgen responsive elements (ARE)-driven firefly luciferase construct and a Renilla luciferase construct in RMPI-1640 media containing 5% CSS. Fortyeight hours later, transfected cells were treated with DMSO, RAD140, or DHT. The luciferase activity was determined using the Dual-Luciferase Reporter Assay (Promega, Madison, WI) as a representation of AR transcription activity and normalized to the activity of Renilla luciferase.
Each set was carried out in triplicate. The values were presented as average fold-changes ± standard deviation (SD) over the vehicle control. Figure S1 ). The efficacy study in T-47D breast cancer cell line-derived xenograft model, established in NOD/Shi-scid/IL-2Rγ null mice, was conducted at WuXi AppTec (Shanghai, China). These xenograft models were supplemented with exogenous estradiol in drinking water 
In vivo efficacy study

Immunohistochemistry (IHC)
Research. Staining and scoring of the samples were performed by a pathologist blinded to the treatment groups.
Western blot (WB) analysis
Tumor lysates from the in vivo studies were prepared using Cell Lysis Buffer with protease and phosphatase inhibitors (Cell Signaling) in a FastPrep Sample Preparation System (MP Biomedicals, Santa Ana, CA). Cell lysates were prepared using Cell Lysis Buffer as described above. Total protein was quantitated and subjected to WB analysis using antibodies against AR (PG-21, EMD Millipore, Billerica, MA; Clone 441, Thermo Fisher), ERα, PR, GAPDH, β-tubulin, and HDAC2 (Cell Signaling).
Gene expression analysis
Total RNA from xenograft samples and cells was extracted using the RNeasy Mini Kit (Qiagen), with a DNase incubation step included to ensure complete removal of genomic DNA. The 
Results
RAD140 binds to AR with high affinity and high specificity
The binding affinity of RAD140 was assessed using fluorescence polarization-based competitive binding assays for AR, ER, PR, and GR and compared against the standard ligands for each nuclear receptor. As positive controls, assays evaluating the binding of the standard ligands including DHT, 17β-estradiol (E2), progesterone, and dexamethasone to AR, ER, PR, and GR, respectively, were performed. In the competitive binding assay against the AR-Fluoromone, RAD140 exhibited 1.6-fold lower AR affinity than DHT ( Figure 1A ). This suggests binding affinity of RAD140 to AR is slightly lower but comparable to that of natural androgen. RAD140 exhibited 33-fold lower affinity to PR compared to progesterone. No binding of RAD140 to ER or GR was detected. In addition, a cellular target spectrum screen was performed to determine the binding selectivity of RAD140 against a broad panel of 165 molecular targets that included many pharmacologically relevant molecules including ion channels, G-protein-coupled receptors (GPCRs), enzymes, and nuclear hormone receptors (Supplementary Table S1 ). No appreciable interaction of RAD140 with any targets screened, other than AR and PR, was detected. These results indicate RAD140 binds to AR with high affinity and specificity.
RAD140 is a potent tissue-selective AR agonist
SARMs are selective AR ligands that have been shown to act as agonists or antagonists in a tissue-context-dependent manner (32) . We previously demonstrated that RAD140 exhibits differential activity in prostate versus in the muscle (30) . To further assess the activity of RAD140 on AR transcription in tissue-context, an AR reporter assay was performed in ZR-75-1, a human breast cancer cell line expressing endogenous AR and ER (21) , and the AR-positive prostate cancer cell line LNCaP (29) . Dose responses by RAD140 were compared to the known AR agonist DHT. Treatment of steroid-depleted ZR-75-1 cells with 1, 10, and 100 nM RAD140 induced AR transcription activity by 1.9 to 2.9-fold, comparable to the induction seen with DHT at the same concentrations ( Figure 1B , left). In contrast, in the low passage, androgen-sensitive LNCaP cells treated with RAD140 at 0.1 to 10 nM, no induction of AR activity was observed while DHT at 1 or 10 nM led to more than a 10-fold induction of AR transcription activity ( Figure   1B , right). In order to rule out the possibility that the attenuated AR activity of RAD140 is due to the expression of a mutant AR T877A in LNCaP cells, we also performed AR reporter assay in PC3-AR cells which express ectopic wildtype AR (29) . Similar to the finding in LNCaP cells, RAD140 exhibited much attenuated activity on ectopic wildtype AR in prostate cancer cells 
RAD140 monotherapy suppresses the growth of AR/ER+ breast cancer patient-derived xenograft (PDX) models
It has been previously reported that DHT inhibits the proliferation of ER positive breast cancer cells driven by supplemental estradiol (21) . We evaluated the activity of RAD140 and DHT in an estrogen-independent AR/ER+ breast cancer line HCC1428 LTED, in which ER signaling appears to be active as judged by PR expression (Supplementary Figure S1) . RAD140 exhibited inhibitory effect on the proliferation of these endocrine-resistant breast cancer cells at concentrations as low as 10 nM, with an apparent maximal effect seen at 100 nM ( Figure 1D ). Figure S3D) . This observation is consistent with previous clinical experience with anastrozole-fulvestrant combination and preclinical data of fulvestrant-RAD1901 combination, both of which showed such intense ER blockade failed to yield additional benefit (35, 36) . Together, these results indicated that RAD140 as a single agent is effective in inhibiting the growth of AR/ER+ breast cancer xenografts.
We then examined the changes in common breast cancer biomarkers in the HBCx-22 xenografts treated with RAD140 or fulvestrant using IHC. As shown in Figure 2C Treatment with fulvestrant also led to substantial decreases in ER, PR and Ki67 expression, to levels seemingly comparable to those seen with RAD140. Furthermore, the epithelial nature of the terminal tumor mass was confirmed using IHC assays for Cytokeratin (CK) 18 and Vimentin (Supplementary Figure S4) . This suggests SARM and SERD both inhibit the ER pathway and breast cancer cell proliferation.
Pharmacodynamic analysis reveals RAD140-mediated regulation of AR and ER target genes and ESR1
It has been proposed that androgens suppress ER signaling in AR/ER+ breast cancer cells, which may contribute to the anti-proliferative activity (19, 21) . To better understand the mechanism of action of the SARM RAD140 in AR/ER+ breast cancer models, we examined the pharmacodynamic changes with a focus on the AR and ER pathways. In the HBCx-22 model, a profound induction of AR target genes including FKBP5, KLK2, and ZBTB16 was seen in RAD140-treated tumors ( Figure 3A, upper) while the expression of the AR gene was not affected. Fulvestrant, as expected, did not induce the expression of these AR target genes, although a slight increase in AR message was seen. The ER target genes PGR, TFF1, and GREB1 were found to be substantially suppressed in RAD140-treated tumors to levels comparable or even lower than that seen with fulvestrant ( Figure 3A, lower) . Interestingly, in these RAD140-treated tumors, the mRNA expression of ESR1, the coding gene of ER, was profoundly suppressed. In contrast, the fulvestrant-treatment did not lead to appreciable change in ESR1 gene expression. At protein level, both RAD140 and fulvestrant exhibited a profound 
effect in decreasing the expression of ER and PR in HBCx-22 xenografts ( Figure 3B, left) , consistent with the IHC findings described above. Similar decrease in ER and PR expression was seen in HBCx-3 AR/ER+ xenografts treated with RAD140 ( Figure 3B, middle) . In the T-47D xenografts, treatment with RAD140, DHT or fulvestrant, also led to decreased ER and PR expression ( Figure 3B, right) .
Next, the modulation of AR and ER target genes by RAD140 was further examined in vitro. As determined in ARE-luc reporter assay and proliferation assay ( Figure 1B and D) , RAD140 at 100 nM exhibited maximal effects, comparable with DHT at 10 nM, therefore 100 nM was To further understand the global effect of RAD140 on signaling cascades in AR/ER+ breast cancer cells, RNA-seq analysis of HBCx-22 xenografts was performed. We examined a broader range of AR and ER target genes with significantly altered expression in RAD140-treated tumors ( Figure 4A) . The results indicated that in addition to the targets examined by qPCR, RAD140-treated tumors had higher levels of AR-activated genes in addition to those shown in qPCR. A subset of the ER target genes was found to be suppressed in RAD140-treated tumors, consistent with the qPCR findings. Using a stringent filtering criteria (FDR<0.001), we found that globally 86 genes were significantly upregulated and 77 were downregulated by at least 2-fold in RAD140-treated HBCx-22 xenografts ( Figure 4B , Supplementary Tables S3 and S4). In the Gene Ontology analysis, these upregulated genes were found to be most significantly enriched in the metabolic process. This was consistent with the previous report describing the role of AR as a master regulator of central metabolism and biosynthesis in prostate cancer cells (39) . The downregulated genes in RAD140-treated tumors were found to be enriched in categories associated with cell division, DNA replication and cell cycle progression. This negative regulation of gene transcription was in line with previous reports on the transcription suppressor role of AR (40, 41) . These data further confirmed the regulation of AR and ER pathways by RAD140 and suggested a unique mechanism of action of RAD140 via the AR-mediated transcription repression. These data offer evidence for further uncovering the underlying mechanism of RAD140 as a single agent in AR/ER+ breast cancer models.
Enhanced anti-tumor activity of combined administrations of RAD140 with CDK4/6 inhibitor
Given the observed effect of RAD140 on cell cycle and DNA replication-related genes, we hypothesized that combined administration of this SARM and a CDK4/6 inhibitor, which inhibits the phosphorylation and subsequent degradation of Rb, thus blocking cell cycle entry (42) (43) (44) , may produce improved anti-tumor activity in AR/ER+ breast cancer models. Palbociclib, a 
those seen with palbociclib alone. In tumors treated with both RAD140 and palbociclib, the expression of these genes appeared to be further suppressed. Together, the enhanced effect of RAD140-palbociclib combination on the expression of DNA replication-related genes may have contributed to the enhanced inhibition on tumor growth.
Discussion
This study demonstrates for the first time that RAD140, an orally available SARM, is an AR agonist in breast cancer cells and suppresses the growth and proliferation of multiple AR/ER+ breast cancer cell line and xenograft models. The AR pathway was found to be activated in RAD140-treated breast cancer cells and xenografts, while genes within the ER pathway, including ESR1, were suppressed. In addition, RAD140-treatment was found to decrease the expression of DNA-replication related genes in breast cancer cells, consistent with previous report that these genes were suppressed in androgen-treated prostate cancer cells. Combined administration of RAD140 with the CDK4/6 inhibitor palbociclib was more efficacious compared with either of the agents used alone. These findings suggest a distinct mechanism of action of RAD140 which includes the AR-mediated suppression of ESR1 in inhibiting AR/ER+ breast cancer growth.
Accumulating evidence in the recent years have further defined the role of AR in breast cancer and led to renewed interests in evaluating AR-targeted agents for breast cancer. The high prevalence of AR in the predominant ER positive subtype of breast cancers (6), clinical benefit rates as high as 39% seen with androgen-therapy in breast cancer patients progressing on ERtargeted treatments (23, 24) , along with prior experience with steroidal androgens in breast cancer together lend support to the development of a new generation of oral, non-steroidal AR agonists for the treatment of AR/ER+ breast cancer.
Research. 
SARMs are tissue selective AR agonists by design and may offer a novel approach to inhibit the growth of AR/ER+ breast cancers, with substantially attenuated side effects commonly seen with classic non-tissue selective androgens (32, 49) . The activity of RAD140 are AR specific, as evidenced by the similar effects observed with DHT and RAD140 on AR and its downstream targets, along with the reversal of these effects by AR antagonists (Figures 1C and 3C ). In addition, due to its non-steroidal structure, the SARM RAD140 is not subject to further conversion to estrogens by CYP19 aromatase, or to DHT by 5α-reductase, thus reducing the potential risk of stimulating ER positive tumor growth or increasing virilization. As a proof-ofconcept study, we report here that RAD140 treatment inhibited the growth of the breast cancer xenograft models supplemented by exogenous estrogen. Of note, RAD140, and its classic androgen comparator DHT, also inhibited the proliferation of an endocrine-resistant breast cancer cell line model, HCC1428 LTED, suggesting AR agonists may inhibit the growth of ER positive breast cancer models with or without estrogen-supplementation. Furthermore, in multiple PDX models, RAD140 inhibited tumor growth as a single agent and this effect was enhanced by combining with palbociclib. PDX models have been demonstrated to closely recapitulate human tumors with regards to tumor heterogeneity and response to standard-ofcare agents (31, 50) . Indeed, heterogeneity was observed in the PDX models used in this study, as indicated by variable levels of AR, ER, PR expression, suggesting a good representation of the patient tumors with a spectrum of expression levels of these nuclear receptors. Also, the growth pattern and response to RAD140 seen with HBCx-3 and HBCx-22 PDX models, each evaluated in two independent studies (Figures 2A, 5A and Supplementary Figures S3A and   S5A ), seemed to be consistent. This suggests good reproducibility of these studies. Therefore, the efficacy seen with RAD140 in these PDX models may be suggestive of the potential therapeutic benefit in breast cancer patient population. It is worth noting that although RAD140
and fulvestrant led to similar tumor growth inhibition in HBCx-22 tumors, further studies are needed to evaluate the efficacy of RAD140 relative to that of fulvestrant or tamoxifen in Table S2 ). As summarized previously, AR agonists exhibit inhibitory effect on AR/ER+ breast cells but not on AR+/ER-cells (9, 51) . It is conceivable that the varying degree of growth inhibition seen with SARM may be attributed to different ER positivity of these models.
The tissue selectivity of RAD140 is evidenced by potent androgen-like effects in bone and muscle, with much attenuated effects in other androgen-responsive tissues such as prostate and seminal vesicles (30) . Notably, when administered along with testosterone, RAD140 was found to partially antagonize the growth effect of testosterone in prostate and seminal vesicles, suggesting that RAD140 acts as a competitive AR ligand with attenuated activity. Here we demonstrated for the first time that the SARM RAD140 is a potent AR agonist in breast cancer cells. It exhibited much attenuated activity on AR in prostate cancer cells, a finding consistent with the previously described attenuated effect on prostate growth (30) . It has been proposed that the tissue-selective AR activity of SARMs is due to the differential allosteric activation of AR compared to classic androgens, which impacts the recruitment of co-activators needed for ARmediated gene transcription (52, 53 ). An earlier study on the selective estrogen receptor modulator (SERM) tamoxifen showed that its tissue selectivity may be attributed to the differential expression of ER co-activators such as SRC-1 in breast versus endometrial cancer cells (54) . Similarly, it is conceivable that AR upon binding to RAD140 assumes a conformation that only allows the interaction with a subset of co-regulators that are uniquely expressed in breast epithelial cells but not in the prostate. Despite the preclinical evidence and favorable clinical outcome seen with androgens in ER positive breast cancer (9, 10) , improved understanding of the underlying mechanism is needed to further improve the design and development of new AR agonist-based therapy. It has been proposed that activated AR suppresses ER signaling by competing with ER for transcriptional co-activators or directly competing for binding sites, and subsequently leads to inhibited cell proliferation (55, 56) , suggesting a functional interference between these two nuclear receptors.
Here we show AR agonists including RAD140 and DHT activate AR target genes in breast cancer cells in vitro and in vivo, while suppressing a subset of ER target genes. Importantly, we found that treatment with these AR agonists also led to substantial suppression of ER at both mRNA and protein levels. This suggests that AR may negatively regulate ER signaling by two mechanisms: while AR may compete with ER for co-activators (functional interference), it may directly downregulate ER expression (direct suppression). The reduction of ER expression by AR agonists has not been extensively documented but can be seen in a study by Poulin et al. 
